US FDA has given a green signal to the marketing partner of Natco Pharma, Alvogen to market oseltamivir phosphate powder —an antiviral medication used for the treatment of influenza virus types A and B in the body — for oral suspension in the United States.
Natco Pharma said: “Alvogen has received final approval and is the first to market generic equivalent to oseltamivir phosphate, 6 mg/ml powder”.
The Chairman and CEO of Alvogen Robert Wessman, said: “The approval and launch of Alvogen’s oseltamivir phosphate powder for oral suspension is great news for the US patients, who will have access to a more affordable alternative.”
According to IMS Midas data, the annual sales for Oseltamivir suspension amount to the US $312 million in the U.S. market.
Currently, 75 products of Alvogen are in development and pending for FDA approvals for the U.S. market.